echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Analysis on the trend of drug registration in 2017: the heat of class 1 chemicals does not decrease

    Analysis on the trend of drug registration in 2017: the heat of class 1 chemicals does not decrease

    • Last Update: 2017-12-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: Xinhua news agency, Dec 8, 2017, medical network, what is the change of enterprise declaration strategy with the deepening implementation of drug registration reform in 2017? Which varieties are more popular? What are the characteristics? As of November 22, 2017, 77% of domestic product registration applications in 2017 were for chemical drugs, 15% for biological products for treatment, and 4% for biological products for prevention and 4% for traditional Chinese medicine Among the chemical drug applications, 44% are registered in Category 1, and 31% are registered in Category 4 of new registration and category 6 of old registration It can be seen that the reporting of generic drugs on the market in China has recovered Due to the fierce competition of generic drugs, the enthusiasm of drug companies to compete for category 1 chemicals is still high Since this year, the application of category 1 Chemicals has been kept at a high temperature Dongyangguang, Hengrui and Zhengda Tianqing are the three major enterprises applying for the acceptance number of new chemical drugs of category 1 in 2017, with the acceptance number close to 20 The proportion of class 1 new chemical drugs declared by the three enterprises is 29% The products declared by dongyangguang Pharmaceutical Co., Ltd include the raw materials and capsules of hec30654acoh, the new anti Alzheimer's drug, and kangdariwei sodium and tablets The products of hec68498 sodium salt and capsules, hec74647pa raw materials and capsules, and ritapiren raw materials and tablets have not been known about the indications The above products are not included in the priority review and approval list The products declared by Hengrui system include shr0532 raw materials and tablets, shr9549 raw materials and tablets with undetermined indications, shr7280 raw materials and tablets for the treatment of endometriosis, shr8554 raw materials and injections for the treatment of pain, shr9146 raw materials and tablets for the treatment of pain, pyrrolidine maleate raw materials and tablets for the treatment of breast cancer Among them, the production declaration of pyrrolidine maleate raw materials and tablets has been included in the priority review and approval list In addition, Hengrui's c-met ADC (antibody drug conjugate) injection has applied for class 1 new biological product for treatment, which has been approved by FDA in the United States The products declared by Zhengda Tianqing system include tq05105 raw materials and tablets, tq05510 raw materials and capsules, tq-a3326 raw materials and tablets, tqb3455 raw materials and tablets, tqb3456 raw materials and tablets, tqb3616 raw materials and capsules for the treatment of medullary thyroid cancer, non-small cell lung cancer and other tumors Among them, the production declaration of androtinib hydrochloride capsule has also been included in the priority review and approval list In addition to pyrrolidine maleate from Hengrui and enrotinib hydrochloride from Zhengda Tianqing, the products reported for the first class of new drugs include the raw materials and capsules of farobojin (China) and Rosa seta for the treatment of renal anemia, the raw materials and capsules of Hutchison Huangpu fuquitini for the treatment of non-small cell lung cancer, and the injection of nanofloxacin malate and sodium chloride from Zhejiang medicine Among them, Hutchison Huangpu fuquitinib was also included in the priority review and approval list The raw materials and capsules of nanofloxacin malate were approved in 2016 The newly registered classification of chemical drugs refers to the four categories of drugs that domestic applicants copy the original drugs that have been listed in China This kind of drugs should be consistent with the quality and efficacy of the original drugs, which mainly corresponds to the old registration classification of chemical drugs (6 categories) Compared with the four categories of new registration of chemical drugs, the three categories of new registration of chemical drugs have higher requirements, more complex clinical trials and higher costs Therefore, the relatively low-cost chemical drugs newly registered and classified 4 categories of projects have attracted many pharmaceutical enterprises The same is true from the declaration data Since CFDA issued the record system of generic be, in 2017, a total of 115 acceptance numbers of new 4 categories of chemical drugs applied for production According to the statistics of the declaration of new 4 categories (old 6 categories) of chemical drugs in 2017, the number of manufacturers applying for tenofovir dipivoxil fumarate tablets is the largest, with 5 enterprises respectively Shijiazhuang Longze pharmaceutical, Anhui ankehengyi pharmaceutical, Suzhou Terry pharmaceutical, Anhui Baker biopharmaceutical and Hangzhou SUPOR Nanyang pharmaceutical Tenofovir dipivoxil fumarate tablets have been listed in Chengdu Beite, Qilu pharmaceutical, Anhui Baker and Zhengda Tianqing in China, the latter three were approved in 2017, and so many enterprises have applied for listing in the future, with fierce competition Moxifloxacin hydrochloride tablets, viagliptin tablets and gefitinib tablets have four applications respectively The manufacturers of moxifloxacin hydrochloride tablets are Chongqing Huabang pharmaceutical, Nanjing Youke pharmaceutical, Guangdong dongyangguang pharmaceutical and Nanjing Shenghe pharmaceutical Moxifloxacin hydrochloride tablets have not been approved by the first manufacturer Moxifloxacin hydrochloride injection has been listed in two domestic markets, Tiantaishan of Chengdu and Youke of Nanjing After 2016, the clinical enterprises started include Sichuan Guowei, Zhejiang Haizheng, Guilin Nanyao, Hunan Tianji Caotang, Shenzhen xinlitai and Jiangsu Tianyi At present, Beijing Wansheng Pharmaceutical Co., Ltd is the enterprise that moxifloxacin hydrochloride tablets have been included in the priority review and approval list The corresponding manufacturers of viagretin tablets are Qilu pharmaceutical, Nanjing Youke pharmaceutical, Beijing Taide pharmaceutical and Jiangsu Haosen pharmaceutical At present, no first manufacturer has been approved to imitate the tablets Yantai Wanrun Pharmaceutical Co., Ltd has been put on record as be, and Shandong Luoxin and Yangzijiang Pharmaceutical Group Sichuan Hailong have started clinical practice Jifeitini tablets have been applied by Zhengda Tianqing pharmaceutical, Nanjing Youke pharmaceutical, Hunan Kelun pharmaceutical and Jiangsu Hengrui pharmaceutical At present, gefitinib is only the first generic product of Qilu pharmaceutical, which has been included in the priority review and approval list After 2016, the start-up clinical enterprises of gefitinib tablet include Ouyi pharmaceutical, Shanghai chuangnio pharmaceutical, Sichuan medacom Huakang pharmaceutical, Jiangsu Tianshili Diyi pharmaceutical, Dalian Zhenao pharmaceutical, Suzhou Teri pharmaceutical, Zhejiang Huahai pharmaceutical and Yangtze River Pharmaceutical The enterprises are ranked according to the number of application acceptance numbers, and Eucalyptus pharmaceutical industry of Petrochemicals Group ranks first In 2017, the products applied for are dasatinib tablets, metformin hydrochloride tablets and sustained-release tablets, pramipexole hydrochloride tablets, clopidogrel bisulfate tablets, sunitinib malate capsules and tegrilol tablets Among them, metformin hydrochloride tablets, sustained-release tablets and clopidogrel bisulfate tablets have been included in the priority review and approval list, which is expected to be a double reporting product approved quickly In 2017, Zhejiang Huahai pharmaceutical declared duloxetine hydrochloride enteric coated capsules, donepezil hydrochloride monohydrate and donepezil hydrochloride tablets, voriconazole tablets, celadoxin capsules and valsartan hydrochlorothiazide tablets Zhengda Tianqing and Foshan Derui can be tied for the third place Zhengda Tianqing applied for Lenalidomide capsules, Saxagliptin Tablets, Gefitinib Tablets, Ambrisentan tablets, Apixaban Tablets and abirone acetate Among them, at present, only the original research drug for the treatment of prostate cancer has been listed in China Dr redI Laboratory of India, Chengdu Shengdi pharmaceutical, Jiangxi Shanxiang pharmaceutical and Qilu pharmaceutical have applied for clinical application through be filing, and Chengdu Shengdi pharmaceutical has also produced the tablet in 2017 annual report Foshan derico Pharmaceutical Co., Ltd is a subsidiary of fadesheng Technology Co., Ltd and won shares of Sihuan Pharmaceutical Co., Ltd in 2017 Sihuan Pharmaceutical Co., Ltd can further develop the international distribution of preparations by manufacturing the drugs developed by its affiliated research institute of generic drugs in line with the European and American markets, registering and applying to the United States and the European Union In 2017, Foshan derico applied for 2 products, including quetiapine fumarate sustained release tablets and glibenclamide tablets Table 1 in 2017, the top five enterprises (data source: Xianda data v3.2) in the number of new category 4 / old category 6 application acceptance of chemical drugs are the two hot spots of biological products project: the hottest vaccine category and the monoclonal antibody category In the vaccine field where the imported products are obviously superior, the domestic products are also starting to make efforts Domestic declaration of biological products for prevention is mainly vaccine, especially influenza vaccine Shanghai Institute of biological products and Changchun Haiji sub organism have the largest number of applications There are many enterprises applying for the split vaccine of influenza virus, including Hualan biology, Changchun Haiji sub biology and Changchun Changsheng biology The application products of biological products for treatment are mainly McAb Among them, PD-1 antibody drugs and PD-L1 antibody drugs are hot spots PD-1 antibody drugs have been listed in 2 products, PD-L1 antibody drugs have been listed in 3 products in the world, and PD-1 antibody drugs in China have also successively entered phase III clinical, such as Xinda's ibi-308 In 2017, the enterprises applying for a large number of biological products for treatment included Jiahe biopharmaceutical, Sichuan Kelun Botai biopharmaceutical and Jiangsu Hengrui pharmaceutical, each with three product applications McAb R & D can be described as blooming everywhere, and the main pressure will come from drug price and project cost In addition, due to more projects and fewer patients, the clinical recruitment of the project will face competition In recent years, the research and development of traditional Chinese medicine, which has been sluggish in recent years, has finally shown signs of recovery At present, the main focus of the research project is the change of dosage form, mainly oral preparations, especially for children According to the data of the Chinese medicine projects being applied for, the applying enterprises include Hutchison Huangpu pharmaceutical, Jichuan pharmaceutical, Yangzijiang pharmaceutical, Hangzhou Zhongmei Huadong pharmaceutical, Jiangsu Kangyuan pharmaceutical and Yunnan Baiyao group The products are basically oral drugs Jichuan pharmaceutical changed its superior products into syrup, and declared the dandilan antiphlogistic syrup and xiaoerdaiqiaoqingre syrup in 2017 Summary: in 2017, the reporting of chemical drugs on the market in China finally recovered From the perspective of application, the reform of registration laws and regulations can not prevent enterprises from applying for products with great sales potential From the application data of enterprises in 2017, we can see which enterprises actively respond to the reform of registration laws and regulations, and adjust their own product R & D application strategies For example, Hengrui, the first enterprise with a market value of more than 200 billion yuan, has a layout in the hot fields of chemical drugs category 1, category 3, new category 4 and therapeutic biological products In 2017, Zhengda Tianqing and dongyangguang declared class 1 and new class 4 data of chemical drugs Collen is in chemical medicine category 3, biological products for treatment How to win in homogeneous competition will be the next step for enterprises to think about  
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.